Copyright Reports & Markets. All rights reserved.

Global Neurodegenerative Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Neurodegenerative Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Neurodegenerative Drugs Market Size Growth Rate by Product
      • 1.4.2 NMDA
      • 1.4.3 SSRIs
      • 1.4.4 Dopamine Inhibitors
    • 1.5 Market by End User
      • 1.5.1 Global Neurodegenerative Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Research
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Neurodegenerative Drugs Market Size
      • 2.1.1 Global Neurodegenerative Drugs Revenue 2014-2025
      • 2.1.2 Global Neurodegenerative Drugs Sales 2014-2025
    • 2.2 Neurodegenerative Drugs Growth Rate by Regions
      • 2.2.1 Global Neurodegenerative Drugs Sales by Regions
      • 2.2.2 Global Neurodegenerative Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Neurodegenerative Drugs Sales by Manufacturers
      • 3.1.1 Neurodegenerative Drugs Sales by Manufacturers
      • 3.1.2 Neurodegenerative Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Neurodegenerative Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Neurodegenerative Drugs Revenue by Manufacturers
      • 3.2.1 Neurodegenerative Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Neurodegenerative Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Neurodegenerative Drugs Price by Manufacturers
    • 3.4 Neurodegenerative Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Neurodegenerative Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Neurodegenerative Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Neurodegenerative Drugs Sales by Product
    • 4.2 Global Neurodegenerative Drugs Revenue by Product
    • 4.3 Neurodegenerative Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Neurodegenerative Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Neurodegenerative Drugs by Countries
      • 6.1.1 North America Neurodegenerative Drugs Sales by Countries
      • 6.1.2 North America Neurodegenerative Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Neurodegenerative Drugs by Product
    • 6.3 North America Neurodegenerative Drugs by End User

    7 Europe

    • 7.1 Europe Neurodegenerative Drugs by Countries
      • 7.1.1 Europe Neurodegenerative Drugs Sales by Countries
      • 7.1.2 Europe Neurodegenerative Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Neurodegenerative Drugs by Product
    • 7.3 Europe Neurodegenerative Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Neurodegenerative Drugs by Countries
      • 8.1.1 Asia Pacific Neurodegenerative Drugs Sales by Countries
      • 8.1.2 Asia Pacific Neurodegenerative Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Neurodegenerative Drugs by Product
    • 8.3 Asia Pacific Neurodegenerative Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Neurodegenerative Drugs by Countries
      • 9.1.1 Central & South America Neurodegenerative Drugs Sales by Countries
      • 9.1.2 Central & South America Neurodegenerative Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Neurodegenerative Drugs by Product
    • 9.3 Central & South America Neurodegenerative Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Neurodegenerative Drugs by Countries
      • 10.1.1 Middle East and Africa Neurodegenerative Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Neurodegenerative Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Neurodegenerative Drugs by Product
    • 10.3 Middle East and Africa Neurodegenerative Drugs by End User

    11 Company Profiles

    • 11.1 Novartis
      • 11.1.1 Novartis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Novartis Neurodegenerative Drugs Products Offered
      • 11.1.5 Novartis Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Neurodegenerative Drugs Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Merck Serono
      • 11.3.1 Merck Serono Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Merck Serono Neurodegenerative Drugs Products Offered
      • 11.3.5 Merck Serono Recent Development
    • 11.4 Biogen Idec
      • 11.4.1 Biogen Idec Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
      • 11.4.5 Biogen Idec Recent Development
    • 11.5 TEVA Pharmaceuticals
      • 11.5.1 TEVA Pharmaceuticals Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 TEVA Pharmaceuticals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 TEVA Pharmaceuticals Neurodegenerative Drugs Products Offered
      • 11.5.5 TEVA Pharmaceuticals Recent Development
    • 11.6 UCB
      • 11.6.1 UCB Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 UCB Neurodegenerative Drugs Products Offered
      • 11.6.5 UCB Recent Development
    • 11.7 Boehringer Ingelheim
      • 11.7.1 Boehringer Ingelheim Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
      • 11.7.5 Boehringer Ingelheim Recent Development
    • 11.8 Sanofi
      • 11.8.1 Sanofi Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sanofi Neurodegenerative Drugs Products Offered
      • 11.8.5 Sanofi Recent Development
    • 11.9 GlaxoSmithKline
      • 11.9.1 GlaxoSmithKline Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
      • 11.9.5 GlaxoSmithKline Recent Development

    12 Future Forecast

    • 12.1 Neurodegenerative Drugs Market Forecast by Regions
      • 12.1.1 Global Neurodegenerative Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Neurodegenerative Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Neurodegenerative Drugs Market Forecast by Product
      • 12.2.1 Global Neurodegenerative Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Neurodegenerative Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Neurodegenerative Drugs Market Forecast by End User
    • 12.4 North America Neurodegenerative Drugs Forecast
    • 12.5 Europe Neurodegenerative Drugs Forecast
    • 12.6 Asia Pacific Neurodegenerative Drugs Forecast
    • 12.7 Central & South America Neurodegenerative Drugs Forecast
    • 12.8 Middle East and Africa Neurodegenerative Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Neurodegenerative Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Neurodegeneration is a broader term which comprises of different disease namely Parkinson’s disease, Huntington disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. These are the most commonly occurring diseases under the condition “Neurodegeneration”.
      The global Neurodegenerative Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neurodegenerative Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Neurodegenerative Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neurodegenerative Drugs in these regions.
      This research report categorizes the global Neurodegenerative Drugs market by top players/brands, region, type and end user. This report also studies the global Neurodegenerative Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Novartis
      Pfizer
      Merck Serono
      Biogen Idec
      TEVA Pharmaceuticals
      UCB
      Boehringer Ingelheim
      Sanofi
      GlaxoSmithKline

      Market size by Product
      NMDA
      SSRIs
      Dopamine Inhibitors
      Market size by End User
      Hospital
      Research

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Neurodegenerative Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Neurodegenerative Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Neurodegenerative Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Neurodegenerative Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Neurodegenerative Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neurodegenerative Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now